Plasmodium vivax: Comparison of the immune responses between oral and parenteral immunization of rPv54 in BALB/c mice

The merozoite surface protein-1 (MSP-1) from Plasmodium vivax was evaluated as an oral vaccine candidate by cloning and expressing the interspecies conserved block 10 (ICB10) of the MSP-1 from a Korean isolate in Escherichia coli. The expressed fusion protein contained ICB10 and a maltose-binding pr...

Full description

Saved in:
Bibliographic Details
Published inExperimental parasitology Vol. 126; no. 2; pp. 217 - 223
Main Authors Kwon, Myoung-Hee, Kim, Hyung-Hwan, Lee, Ho-Sa, Kim, Tong-Soo, Oh, Chang-Mi, Ahn, Yong-Joo, Hwang, Seo-Kyong, Sohn, Youngjoo, Kim, Hyuck, Lee, Hyeong-Woo
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Inc 01.10.2010
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The merozoite surface protein-1 (MSP-1) from Plasmodium vivax was evaluated as an oral vaccine candidate by cloning and expressing the interspecies conserved block 10 (ICB10) of the MSP-1 from a Korean isolate in Escherichia coli. The expressed fusion protein contained ICB10 and a maltose-binding protein (MBP), rPv54, has a molecular weight of approximately 54 kDa as determined by SDS–PAGE analysis. IgG against rPv54 was successfully produced in BALB/c mice by oral immunization and sustained for more than 4 months. IgG2b was dominantly produced in both oral and parenteral immunizations. The rPv54 increased the frequency of NK, NKT, CD4+ T, CD8+ T, and B cells in both immunizations. IL-5 and TNF-α were increased in both significantly. In conclusion, rPv54 might be a valuable potential vaccine candidate for the oral and parenteral immunization against vivax malaria.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0014-4894
1090-2449
DOI:10.1016/j.exppara.2010.05.001